Osim (O23.SG) +2.2% at $0.93, may end up for first time in 4 sessions on broad market uptick, says Dow Jones.

Shares down 6.7% so far this week after going ex-dividend on Tuesday, but down by even steeper 14.2% so far this month.

“We find no justification for such a sharp fall and see this as an excellent opportunity to enter the stock,” says Macquarie, which has Outperform call with $1.50 target; notes massage-chair maker deserves re-rating given improving profitability in key markets, strong net cash position.

2Q10 earnings more than doubled on-year to $12.1 million on stronger margins, sales. Current gains not accompanied by firm volume. Shares expected to remain below 10-day moving average, last at $0.97.